𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Expression profiling analysis of the CD5+ diffuse large B-cell lymphoma subgroup: Development of a CD5 signature

✍ Scribed by Miyuki Suguro; Hiroyuki Tagawa; Yoshitoyo Kagami; Masataka Okamoto; Koichi Ohshima; Hiroshi Shiku; Yasuo Morishima; Shigeo Nakamura; Masao Seto

Book ID
108583704
Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
311 KB
Volume
97
Category
Article
ISSN
1347-9032

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The therapeutic effect of rituximab on C
The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma
✍ Rie Hyo; Naoto Tomita; Kengo Takeuchi; Tomohiro Aoshima; Atsuko Fujita; Hideyuki πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 111 KB

## Abstract The prognosis of diffuse large B‐cell lymphoma (DLBCL) has improved markedly in recent years of rituximab era. The prognosis of __de novo__ CD5‐positive DLBCL is reported to be poor, but the effect of rituximab on this type of lymphoma remains unclear. To investigate the effect of ritux

Analysis of chromosomal imbalances in de
Analysis of chromosomal imbalances in de novo CD5-positive diffuse large-B-cell lymphoma detected by comparative genomic hybridization
✍ Sivasundaram Karnan; Hiroyuki Tagawa; Ritsuro Suzuki; Miyuki Suguro; Motoko Yama πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 107 KB

We recently demonstrated that the prognosis for de novo CD5-positive (CD5+) diffuse large-B-cell lymphoma (DLBCL) is markedly worse than that for CD5-negative (CD5-) DLBCL. Our findings also suggested that on the basis of its clinical features CD5+ DLBCL may constitute a unique disease category. How